

SUPPLEMENTARY FIGURES





Fig S1. Enlarged merged images from Figure 1.

## NRVM



## ARVM









Fig S1. Enlarged merged images from Figure 2.




**Fig S3. siRNA-mediated knockdown of IP<sub>3</sub>R-1, -2 and -3.** Western blot analysis of 293T (A) and AR42J (B) cell lines transfected with control siRNA and siRNA oligos specific for each IP<sub>3</sub>R isoform as indicated. IP<sub>3</sub>R-1 siRNA significantly reduced endogenous IP<sub>3</sub>R-1 expression in 293T where control siRNA did not. Similarly IP<sub>3</sub>R-3 siRNA significantly reduced IP<sub>3</sub>R-3 expression. Both siRNAs were specific for the individual isoforms. Triple IP<sub>3</sub>R siRNA transfection inhibited the expression of both IP<sub>3</sub>R-1 and -3 in 293T cells (A). IP<sub>3</sub>R-2 expression was below detection levels in 293T cells. (B) To probe the efficiency of IP<sub>3</sub>R-2 siRNA, we used AR42J cells which express high amounts of this isoform. IP<sub>3</sub>R-2 siRNA completely inhibited IP<sub>3</sub>R-2 expression, and also partially reduced IP<sub>3</sub>R-1 levels. IP<sub>3</sub>R-3 expression was below detection levels in AR42J cells. In both panels, alpha-fodrin was used as loading control. (C) IP<sub>3</sub>R expression levels in neonatal rat ventricular cardiomyocytes co-transfected with siRNA to the individual isoforms and YFP to identify transfected cells. In the color merge panel, separation of green and red channels is indicative of knockdown.



**Fig. S4. Expression of IP<sub>3</sub>R isoforms in non-failing and end stage heart failure samples.** Immunofluorescence staining of non-failing human left ventricle (Control 2 and 3) and left ventricular heart failure samples (Patient 2 and 3). Column 1 is stained with  $\alpha$ -actinin to label sarcomeres. Column 2 is stained with indicated IP<sub>3</sub>R antibodies. Column 3 is DAPI staining of the nucleus. Column 4 is the merged images of each row.



**Fig. S5. Histogram of cardiomyocyte cell size distribution after ET-1 treatment of control and triple IP<sub>3</sub>R knockdown of NRVMs.** Neonatal ventricular cardiomyocytes cell size distribution in control (Panel A) and triple IP<sub>3</sub>R siRNA transfected cells (Panel B) treated with ET-1 for 48 hrs. Control cells have a larger cell size distribution compared to triple IP<sub>3</sub>R KD cells.



**Fig S6. Plot of cytosolic GCaMP6s versus Fura-2 oscillation frequency.** Cytosolic GCaMP6s was imaged simultaneously with cytosolic Fura-2 oscillation in neonatal cardiomyocytes and relative oscillation frequencies from each indicator were quantified. Each symbol represents a single coverslip averaging 5-10 cells for a total of three separate experiments. Frequency data was quantified from 20 seconds bins.

	Control 1	Control 2	Control 3	Patient 1 HF	Patient 2 HF	Patient 3 HF
<b>NYHA Class</b>	1	1	1	4	3.5	4
<b>Age</b>	43	19	36	57	64	60
<b>Sex</b>	F	F	M	M	M	M
<b>Hypertension</b>	-	-	-	Stage 1	Stage 1	-
<b>LVEDD</b>	-	3.6	4.5	7.2	6.7	5.9
<b>LVPWd</b>	-	0.7	1	1.4	1.3	0.6
<b>EF</b>	60%	68%	60%	20%	20%	20%

**Supplementary Table 1. Clinical characteristics of patient samples.** Control samples were obtained from hearts that were declined for transplantation due to non-cardiac reasons. Patient 1-3 samples were obtained from patients that suffered with end stage heart failure. NYHA indicates New York Heart Association; Stage 1 hypertension, systolic pressure ranging from 140 to 159 mm Hg or a diastolic pressure ranging from 90 to 99 mm Hg; LVEDD, left ventricular end diastolic diameter- normal range 4.2-5.9 cm; EF, Ejection Fraction, normal EF ranges from 55-70%; LVPWd, Left ventricular posterior wall end diastole and end systole-normal range 0.6-1.1 cm. A dash indicates data not available.